Poster on planned phase II study at ASCO

May 30, 2017

Copenhagen, Denmark – May 30, 2017: Dr Anders Mellemgaard who is a leading clinician at University of Copenhagen Herlev Hospital in Denmark, will be presenting a poster at the June 2-6 ASCO Conference in Chicago.

Other news

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

November 9, 2021

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial

September 14, 2021

back to news overview